











194High prevalence of polycystic ovary syndrome in
women with mild hirsutism and no other significant
clinical symptoms
Gaetana Di Fede, M.D., Pasquale Mansueto, M.D., Ilenia Pepe, M.D., Giovam Battista Rini, M.D.,
and Enrico Carmina, M.D.
Department of Clinical Medicine, University of Palermo, Palermo, Italy
Objective: To verify the conclusions of the Endocrine Society Guidelines that patients with mild hirsutism and no
other important clinical signs (menstrual irregularities, infertility, central obesity, acanthosis nigricans, rapid pro-
gression of the hirsutism, clitoromegaly) should not be further studied.
Design: Retrospective study in patients referred because of mild hirsutism and no other clinical signs.
Setting: Department of Clinical Medicine of the University of Palermo.
Patient(s): One hundred fifty-two patients with mild hirsutism.
Intervention(s): Measurement of serum testosterone, dehydroepiandrosterone sulfate, 17-OH-Progesterone, as-
sessment of ovulation by measurement of progesterone in 21 to 24 days and ovarian ultrasound.
Result(s): In 72 (47%) patients a diagnosis of polycyctic ovarian syndrome (PCOS) was performed. Polycyctic
ovarian syndrome patients included 56 patients with the mild ovulatory form (OV-PCOS) but also 16 patients
with the anovulatory form (classic PCOS). Three (2%) patients had nonclassic adrenal hyperplasia.
Conclusion(s): Because of the high prevalence of PCOS and the possibility of finding nonclassic 21-hydroxylase
deficiency, patients with mild hirsutism need a diagnostic evaluation that should include 17-hydroxyprogesterone
measurement plus assessment of ovulation and ovarian ultrasound. (Fertil Steril 2010;94:194–7.2010 byAmer-
ican Society for Reproductive Medicine.)
Key Words: Hyperandrogenism, PCOS, hirsultism, nonclassic adrenal hyperplasiaHirsutism is a common condition in which women present
terminal hairs with a male-like pattern (1). In most patients,
hirsutism is a sign of disorders that may produce significant
morbidity (2). Therefore, treatment of hirsutism has to be pre-
ceded by a careful diagnostic evaluation, and the findings will
largely influence the therapeutic decisions.
Recently, the Endocrine Society has published a clinical
guideline on evaluation and treatment of hirsutism (3). This
guideline, although useful and based on review of available
evidence, presents some conclusions that contrast with the
personal experience of the invesitgator and with that of
many experts. In particular, the investigators stated that pa-
tients with mild hirsutism and no other important clinical
signs (menstrual irregularities, infertility, central obesity,
acanthosis nigricans, rapid progression of the hirsutism, clit-
oromegaly) should not be further studied, although theyDecember 15, 2008; revised February 11, 2009; accepted
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quality evidence (3).
Of course, personal experiences cannot be considered
when preparing guidelines based on available evidence.
Therefore, in this study, we wished to verify what diagnosis
has been performed during the last 10 years in our department
in patients referred because of mild hirsutism who did not
present the clinical signs indicated in the guideline of Endo-
crine Society.MATERIALS AND METHODS
Between 1999 and 2008, 420 women were studied because of
hirsutism in the Endocrine Unit of the Department of Clinical
Medicine, at the University of Palermo.
Hirsutism was assessed by Ferriman-Gallwey-Lorenzo
scores (4) (patients with eight or more scores were considered
hirsute). Three hundred forty-four patients presented a mild
hirsutism (8–15 FGL scores), whereas 76 had a moderate–se-
vere hirsutism (>15 FGL scores).
Only the records that contained at least the following stud-
ies were considered useful for inclusion of hirsute patients in
this study: physical examination, body mass index (BMI),0015-0282/$36.00
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waist circumference (WC), age, and characters of menstrual
cycles.
Physical examination showing medium–severe hirsutism
(>15 FGL scores), clitoromegaly, acanthosis nigricans,
BMIR30 or WCR88 cm represented a criterion of exclu-
sion. Menstrual cycles shorter than 25 days and longer than
34 dayswere considered abnormal, and represented a criterion
of exclusion. History of rapid progression of hirsutism in the
last few months represented another criterion of exclusion.
One hundred eighty women, presenting mild hirsutism,
were excluded because of clinical features (BMI, WC, clitoro-
megaly, acantosis nigricans, abnormalmenses),whereas 12pa-
tients with mild hirsutism were excluded because of an
incomplete diagnostic workup. One hundred fifty-twowomen,
presentingmild hirsutism (8–15 FGL scores) and no criteria of
exclusion, were included in this study. In these patients, serum
levels of testosterone (T), dehydroepiandrosterone sulphate
(DHEAS), 17-hydroxyprogesterone (17OHP), progesterone
(P), and pelvic sonography were evaluated at the moment of
their referral to our endocrine clinic.
Serum androgens and 17OHP were measured during fol-
licular phase (days 5–8), whereas serum P was determined
on days 21–24 of the menstrual cycle.
Serum hormone levels were quantified by well-established
methods that had been validated previously in our laboratory.
All steroids were measured by specific RIAs after extraction
using previously described methods (5). In all assays, intraas-
say and interassay coefficients of variation did not exceed 6%
and 15%, respectively.
Biochemical hyperandrogenism was defined as serum
T > 60 ng/dL (>2.08 nmol/L) and/or serum DHEAS
R3,000 mg/L (R7.8 mmol/L). These values of hyperandro-
genism have been previously calculated in our population
with the same assays (6).
Increased serum 17OHP was defined as serum 17OHP >3
mg/L (>9.1 nmol/L). In patients with mildly increased serum
17OHP (<10 mg/L and>3 mg/L), increased 17OHP response
to ACTH administration (1 mg IV with blood samples at 0,
30, and 60 minutes) was required for diagnosis of nonclassic
21hydroxylase deficiency (7).
Anovulation was defined as serum P <3 ng/mL (<9.54
nmol/L). In patients with normal menses, at least two consec-
utive menstrual cycles were studied, and finding of low levels
of serum P (<3 ng/mL) in both cycles indicated the presence
of chronic anovulation.
Pelvic ultrasound had to report ovarian size (by measure-
ment of the main three ovarian diameters in both ovaries)
and presence, size, and number of ovarian microcysts. Both
data obtained by abdominal and transvaginal ultrasounds
were considered useful for the diagnosis.
The presence of polycystic ovaries was established by the
presence of 10 or more peripherally oriented cystic structures
in one ultrasonographic plane, each of which measured 2 toFertility and Sterility10 mm in diameter, arranged around a dense stroma (8).
Ovarian volume was calculated by the formula p/6 (D1 
D2 D3), where the dimensions (D) of length, width, and
thickness were used. The size of both ovaries was assessed
and mean ovarian size was calculated. According to our
data of normal women, increased ovarian size indicates that
the mean ovarian size was larger than 7.5 cc3 (9). Similar
data have been reported by others (10).
The diagnosis of the different androgen excess disorders
was performed according previously reported criteria (11).
In particular, polycystic ovary syndrome (PCOS) was diag-
nosed in hirsute patients presenting chronic anovulation
and/or polycystic ovaries (12, 13). Diagnoses of PCOS in-
cluded both ovulatory (OV-PCOS) and anovulatory (classic
PCOS, PCOS) form. Ovulatory PCOS was diagnosed in pa-
tients having normal ovulatory menses, hyperandrogenism
(clinical finding of hirsutism was sufficient), and polycystic
ovarian morphology (13). Classic PCOS was diagnosed in
patients having chronic anovulation and hyperandrogenism
(clinical finding of hirsutism was sufficient). Nonclassic
21-adrenal hyperplasia was diagnosed on the basis of in-
creased serum 17OHP (>10 mg/L) (>30.3 nmol/L) or mildly
increased serum 17OHP (>3<10 mg/L) with an increased re-
sponse to ACTH (D17OHP>5 mg/L with a 17OHP peak>10
mg/L). Non-PCOS hyperandrogenism was diagnosed in hir-
sute patients presenting ovulatory cycles and normal ovaries
at the ultrasound study. According their androgen levels,
these patients were further distinguished in idiopathic hyper-
androgenism and idiopathic hirsutism (13).
Fifty normal nonhirsute controls were also studied. They
were students or young doctors, matched for age and BMI,
who volunteered for this study. All studied controls showed
normal androgen levels, normal ovulatory cycles, and normal
ovaries.
Institutional review board approval was obtained, and all
patients and controls gave written consent. All subjects
were considered to be sedentary, and were not dieting or re-
ceiving any medications. No subject received hormonal med-
ications for at least 3 months before the study.Statistical Analysis
A two-group comparison of continuous variables was per-
formed using a two-sample t test with adjustment for noncon-
stancy of variance, when necessary. A Bartlett test was used
to evaluate homogeneity of variance. More than two group
means were compared using analysis of variance with post
hoc least-squares means pairwise comparisons. All data are
presented as mean  standard deviation.RESULTS
The mean clinical and hormonal data of 152 patients with
mild hirsutism are presented in Table 1. Patients and controls
were similar for age and BMI. However, hirsute patients pre-
sented significantly higherWC (P<.01) FGL scores (P<.01),195
TABLE 1
Clinical data and serum androgen values in 152 women with mild hirsutism (FGL scores 8 to 15) and 50
nonhirsute controls.
Age (y) BMI WC (cm) FGL scores T (ng/dL) DHEAS (mg/L)
Patients with mild hirsutism 24.2  5 22.7  2.3 78  4.9a 9.9  2.5a 64  28a 2.6  1.2a
Controls 24.6  3 22  2 76  4 3  1 34  13 2.1  0.4
Normal range <25 <80 0-5 20–60 1.2–2.9
Note: BMI ¼ body mass index; WC ¼ waist circumference; DHEAS ¼ dehydroepiandrosterone sulfate. Mean  2 SD
values of controls was used to calculate the normal ranges of FGL scores, T, and DHEAS. Normal limits of BMI and
WC were derived by epidemiologic studies in the same population.
a P< .01 compared to controls.
Di Fede. PCOS in mildly hirsute women. Fertil Steril 2010.serum T (P<.01), and serum DHEAS (P<.01) than control
women.
The analysis of individual values showed that 86 (57%) pa-
tients presented increased values of T, whereas 37 (24.5%)
hirsute women had increased serum levels of DHEAS.
Because most patients with increased DHEAS had also in-
creased T, the total number of hyperandrogenic women was
91 (59.9% of the women with mild hirsutism). Seventy pa-
tients (46%) with mild hirsutism had values of WC between
80 and 87 cm.
Table 2 shows the distribution of different androgen excess
disorders in the patients with mild hirsutism. Most patients
(80 ¼ 52.6%) had a non-PCOS disorder that in 43 women
were associated with increased androgen levels (idiopathic
hyperandrogenism), whereas in 34 women T and DHEAS
were normal (idiopathic hirsutism).
Three patients presented a nonclassic 21-hydroxylase defi-
ciency (NCAH).
Polycystic ovary syndrome was found in 72 (47.4%)
women with mild hirsutism and no other clinical signs. Most
PCOS women with mild hirsutism were ovulatory (56 ¼
36.8%), but 16 were anovulatory (classic PCOS: 10.6%).
Values of WC <80 cm and between 80 and 87 cm did not
distinguish between PCOS and non-PCOS patients.TABLE 2
Diagnosis in 152 women with mild hirsutism.
Patients PCOS OV-PCOS NCAH No PCOSa
Number 16 56 3 77
% 10.6 36.8 2 50.6
Note: PCOS¼ polycyctic ovary syndrome; OV-PCOS¼
ovulatory form PCOS; NCAH ¼ nonclassic 21-hy-
droxylase deficiency.
a No PCOS indicates hirsute patients where no diagno-
sis of PCOS or NCAH was performed.
Di Fede. PCOS in mildly hirsute women. Fertil Steril 2010.DISCUSSION
The data of this retrospective study confirm the clinical expe-
rience that severity of hirsutism cannot be used to distinguish
patients. The addition of clinical data such as normality of
menses and normal BMI and WC, although increasing the
probability of finding a non-PCOS disorder, does not rule
out the possibility of a diagnosis of PCOS or nonclassic adre-
nal hyperplasia. In our study, half (47.4%) of the patients with
mild hirsutism and no other clinical signs had PCOS (accord-
ing to Rotterdam or AES criteria) or nonclassic adrenal hy-
perplasia (2%). In addition, whereas most patients with
PCOS had the mild ovulatory form, 16 (10.6%) women had
the classic anovulatory phenotype that corresponds to previ-196 Di Fede et al. PCOS in mildly hirsute womenous NIH diagnostic criteria for diagnosis of PCOS (14). On
the other hand, it is well known that although in general pop-
ulation normal menses are generally associated to ovulatory
cycles, in hyperandrogenic women anovulation may be pres-
ent in a significant proportion of women with apparently nor-
mal cycles. Because of this, previous studies have found that
the anovulatory form of PCOS may present in 10% to 20% of
normally cycling women (15, 16).
Although this was a retrospective study, we do not believe
it represents a motive of bias. In fact, during last 10 years, in
our department, all patients with hirsutism did a similar initial
study, independently on severity of hirsutism. Of course,
a prospective study may be needed to confirm our experience.
It is important to observe that most of the hirsute patients
referred to our department during the last 10 years presented
a mild hirsutism. In fact, out of 420 hirsute patients, 344 pa-
tients presented a mild hirsutism (8–15 FGL scores), whereas
76 had a moderate–severe hirsutism (>15 FGL scores).
Therefore, mild hirsutism is present in most hirsute patients
(82%) and exclusion of these patients from a careful study
may restrain from performing the diagnosis of PCOS in a sig-
nificant number of patients.
Because prevalence of PCOS (National Institutes of Health
defined) in the general female population is around 6% (17),
our findings show that the presence of mild hirsutism, withoutVol. 94, No. 1, June 2010
abdominal obesity or anovulation, increases only slightly
(about 1.8 times) the PCOS prevalence (at least of more se-
vere phenotype) over the general population. However, it
has to be remembered that this is just a subgroup of hirsute
patients. Most patients with mild hirsutism were excluded
by this study because of obesity (at least abdominal obesity)
and/or anovulation and, whereas in these patients the preva-
lence of classic PCOS was not assessed, it is probable that an-
ovulatory PCOS is more common in patients with more
severe phenotype. Similarly, prevalence of classic PCOS
may be higher in patients with severe hirsutism. In addition,
the prevalence of the milder ovulatory form was highly in-
creased, and also this PCOS phenotype is able to determine
a higher metabolic and cardiovascular risk (18).
Our data indicate that the conclusions of the recent Endo-
crine Society guideline, that stated that patients with mild hir-
sutism should not be further investigated, cannot be accepted.
In our view, it is just the opposite. In patients with hirsutism
and menstrual irregularities the diagnosis of PCOS does not
require further data, and although it may be useful to have an-
drogen levels and ovarian ultrasound study, all it does not
modify the diagnosis or the treatment of the patients. Proba-
bly, in these women, it is more important to evaluate the met-
abolic pattern (serum lipids, oral glucose tolerance test,
insulin resistance) to understand what other problems these
patients may have.
On the contrary, the patients with mild hirsutism and no
clinical signs require further investigation because the possi-
ble diagnoses are completely different and may require dif-
ferent treatments or different need of follow-up. Because of
this, we suggest that all patients with mild hirsutism and no
clinical signs should perform an ovarian sonography, an as-
sessment of ovulation, and the measurement of serum
17OHP. Although we continue doing our reliable noncom-
mercial androgen assays for research purposes, in clinical
practice, especially in patients with mild hirsutism and no
other clinical signs, there is no need to evaluate serum andro-
gens because clinical hyperandrogenism is already present
and commercial androgen assays are of little value.REFERENCES
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